Bristol’s Opdivo Continues Slide, But First-Line Lung Offers Optimism
Executive Summary
Sales of the Bristol PD-1 inhibitor dropped 9% year-over-year but the company says approvals in first-line NSCLC are off to a good start. Q2 saw growth for Eliquis and Revlimid despite pandemic impact.
You may also be interested in...
BMS Sighs In Relief As Opdivo Returns To Sales Growth
With full-year 2020 and Q1 sales down due to pandemic, the company celebrates the PD-1 therapy’s growth in Q2. CAR-T products Breyanzi, Abecma are off to solid launches but face manufacturing hurdles.
BMS Has A Lot Of Ground To Make Up Ahead Of Patent Expiries
Bristol Myers Squibb is struggling to restore Opdivo’s growth and COVID-19 sales impacts didn’t help in Q1. New indications are coming but new products, like Zeposia, are slow to add significant revenue.
BMS Revenues Soar, But High-Flying Revlimid Is A Big Driver
The Celgene acquisition gave BMS a new top-selling drug but Revlimid revenue will start to decline as soon as next year and it is likely to take many new products to replace it.